Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Ergoloid-mesylates
2. Ergoloid_mesylate
3. Chebi:181460
4. Nicotinebi-l-(+)-tartrate
5. 12'-hydroxy-2'-isopropyl-3',6',18-trioxo-5'-tert-pentyl-9,10-dihydroergotaman #
6. N-[2-hydroxy-7-(2-methylbutan-2-yl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-g]quinoline-9-carboxamide
Molecular Weight | 591.7 g/mol |
---|---|
Molecular Formula | C33H45N5O5 |
XLogP3 | 3.5 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 591.34206955 g/mol |
Monoisotopic Mass | 591.34206955 g/mol |
Topological Polar Surface Area | 118 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 1180 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 7 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Dihydroergotoxine Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dihydroergotoxine Mesylate, including repackagers and relabelers. The FDA regulates Dihydroergotoxine Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dihydroergotoxine Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dihydroergotoxine Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dihydroergotoxine Mesylate supplier is an individual or a company that provides Dihydroergotoxine Mesylate active pharmaceutical ingredient (API) or Dihydroergotoxine Mesylate finished formulations upon request. The Dihydroergotoxine Mesylate suppliers may include Dihydroergotoxine Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Dihydroergotoxine Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dihydroergotoxine Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Dihydroergotoxine Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Dihydroergotoxine Mesylate DMFs exist exist since differing nations have different regulations, such as Dihydroergotoxine Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dihydroergotoxine Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Dihydroergotoxine Mesylate USDMF includes data on Dihydroergotoxine Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dihydroergotoxine Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dihydroergotoxine Mesylate suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dihydroergotoxine Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dihydroergotoxine Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dihydroergotoxine Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dihydroergotoxine Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dihydroergotoxine Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dihydroergotoxine Mesylate suppliers with NDC on PharmaCompass.
Dihydroergotoxine Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dihydroergotoxine Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dihydroergotoxine Mesylate GMP manufacturer or Dihydroergotoxine Mesylate GMP API supplier for your needs.
A Dihydroergotoxine Mesylate CoA (Certificate of Analysis) is a formal document that attests to Dihydroergotoxine Mesylate's compliance with Dihydroergotoxine Mesylate specifications and serves as a tool for batch-level quality control.
Dihydroergotoxine Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Dihydroergotoxine Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dihydroergotoxine Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Dihydroergotoxine Mesylate EP), Dihydroergotoxine Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dihydroergotoxine Mesylate USP).
LOOKING FOR A SUPPLIER?